We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Pfizer (PFE - Free Report) ended the recent trading session at $26.58, demonstrating a -0.3% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.04% for the day. Elsewhere, the Dow lost 0.03%, while the tech-heavy Nasdaq added 0.03%.
The drugmaker's stock has dropped by 2.06% in the past month, falling short of the Medical sector's loss of 0.6% and the S&P 500's gain of 2.57%.
The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its earnings on May 1, 2024. The company's upcoming EPS is projected at $0.57, signifying a 53.66% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $14 billion, down 23.44% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $2.21 per share and a revenue of $59.86 billion, demonstrating changes of +20.11% and +2.32%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.05% decrease. Pfizer is holding a Zacks Rank of #3 (Hold) right now.
With respect to valuation, Pfizer is currently being traded at a Forward P/E ratio of 12.05. This expresses a discount compared to the average Forward P/E of 14.31 of its industry.
We can also see that PFE currently has a PEG ratio of 1.2. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.74 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 206, finds itself in the bottom 19% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Declines More Than Market: Some Information for Investors
Pfizer (PFE - Free Report) ended the recent trading session at $26.58, demonstrating a -0.3% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.04% for the day. Elsewhere, the Dow lost 0.03%, while the tech-heavy Nasdaq added 0.03%.
The drugmaker's stock has dropped by 2.06% in the past month, falling short of the Medical sector's loss of 0.6% and the S&P 500's gain of 2.57%.
The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its earnings on May 1, 2024. The company's upcoming EPS is projected at $0.57, signifying a 53.66% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $14 billion, down 23.44% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $2.21 per share and a revenue of $59.86 billion, demonstrating changes of +20.11% and +2.32%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.05% decrease. Pfizer is holding a Zacks Rank of #3 (Hold) right now.
With respect to valuation, Pfizer is currently being traded at a Forward P/E ratio of 12.05. This expresses a discount compared to the average Forward P/E of 14.31 of its industry.
We can also see that PFE currently has a PEG ratio of 1.2. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.74 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 206, finds itself in the bottom 19% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.